X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (37964) 37964
Newsletter (599) 599
Newspaper Article (258) 258
Book Chapter (37) 37
Publication (16) 16
Magazine Article (14) 14
Conference Proceeding (9) 9
Book / eBook (8) 8
Dissertation (7) 7
Trade Publication Article (5) 5
Reference (2) 2
Book Review (1) 1
Government Document (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23315) 23315
animals (19649) 19649
epidermal growth factor - pharmacology (11431) 11431
epidermal growth factor (10331) 10331
mice (8944) 8944
female (8593) 8593
oncology (7924) 7924
receptor, epidermal growth factor - metabolism (6624) 6624
male (6496) 6496
cells, cultured (6391) 6391
rats (6103) 6103
biochemistry & molecular biology (6091) 6091
cell biology (6006) 6006
cell line, tumor (5916) 5916
phosphorylation (5856) 5856
expression (5535) 5535
cancer (5412) 5412
signal transduction (4874) 4874
pharmacology & pharmacy (4452) 4452
cell line (4413) 4413
receptor, epidermal growth factor - antagonists & inhibitors (4173) 4173
epidermal-growth-factor (3934) 3934
antineoplastic agents - pharmacology (3858) 3858
signal transduction - drug effects (3497) 3497
cell division - drug effects (3475) 3475
epidermal growth-factor (3374) 3374
apoptosis (3340) 3340
activation (3299) 3299
receptor, epidermal growth factor - genetics (3226) 3226
research (3213) 3213
proteins (3153) 3153
cell proliferation - drug effects (3106) 3106
epidermal growth factor - metabolism (3035) 3035
mutation (2991) 2991
tumor cells, cultured (2969) 2969
kinases (2865) 2865
growth-factor receptor (2766) 2766
egfr (2653) 2653
dose-response relationship, drug (2634) 2634
cells (2578) 2578
analysis (2568) 2568
tumors (2513) 2513
gene expression (2504) 2504
protein kinase inhibitors - pharmacology (2470) 2470
epidermal growth factor receptors (2424) 2424
quinazolines - pharmacology (2375) 2375
research article (2335) 2335
chemotherapy (2201) 2201
kinetics (2192) 2192
apoptosis - drug effects (2128) 2128
proliferation (2124) 2124
epidermal growth factor receptor (2110) 2110
enzyme inhibitors - pharmacology (2106) 2106
time factors (2069) 2069
breast cancer (2049) 2049
middle aged (2038) 2038
cell proliferation (1991) 1991
blotting, western (1951) 1951
tyrosine (1946) 1946
inhibition (1907) 1907
gefitinib (1902) 1902
multidisciplinary sciences (1896) 1896
in-vitro (1887) 1887
antineoplastic agents - therapeutic use (1880) 1880
adult (1874) 1874
growth factors (1867) 1867
care and treatment (1863) 1863
transfection (1847) 1847
medicine (1826) 1826
lung neoplasms - drug therapy (1790) 1790
phosphorylation - drug effects (1753) 1753
metastasis (1717) 1717
lung cancer (1701) 1701
factor receptor (1689) 1689
physiological aspects (1687) 1687
endocrinology & metabolism (1685) 1685
gene-expression (1681) 1681
aged (1656) 1656
physiology (1648) 1648
growth (1635) 1635
molecular sequence data (1600) 1600
immunohistochemistry (1597) 1597
receptor (1590) 1590
medicine, research & experimental (1575) 1575
mice, nude (1574) 1574
rna, messenger - metabolism (1557) 1557
differentiation (1547) 1547
health aspects (1529) 1529
cell growth (1520) 1520
genetic aspects (1495) 1495
cell survival - drug effects (1488) 1488
egf (1487) 1487
egf receptor (1475) 1475
cancer therapies (1448) 1448
carcinoma, non-small-cell lung - drug therapy (1426) 1426
rats, sprague-dawley (1425) 1425
protein (1419) 1419
enzyme activation (1414) 1414
erbb receptors - metabolism (1411) 1411
therapy (1408) 1408
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38573) 38573
Japanese (385) 385
Chinese (292) 292
Russian (130) 130
French (60) 60
German (47) 47
Spanish (21) 21
Hungarian (14) 14
Portuguese (12) 12
Italian (6) 6
Dutch (5) 5
Norwegian (4) 4
Polish (4) 4
Bulgarian (2) 2
Croatian (1) 1
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncogene, ISSN 1476-5594, 2010, Volume 29, Issue 49, pp. 6485 - 6498
Journal Article
Cancer science, ISSN 1347-9032, 2016, Volume 107, Issue 7, pp. 1039 - 1046
...‐8201a is a human epidermal growth factor receptor 2 (HER2)‐targeting antibody–drug conjugate prepared using a novel linker... 
topoisomerase I inhibitor | T‐DM | HER2 | bystander killing | Antibody‐drug conjugate | T-DM | Antibody-drug conjugate | HODGKINS LYMPHOMA | GEMTUZUMAB OZOGAMICIN | ADVANCED BREAST-CANCER | BRENTUXIMAB VEDOTIN | ACUTE MYELOID-LEUKEMIA | TRASTUZUMAB EMTANSINE | CHALLENGES | THERAPY | ONCOLOGY | EXPRESSION | CATHEPSIN-B | Receptor, ErbB-2 - genetics | Breast Neoplasms - immunology | Humans | Ado-Trastuzumab Emtansine | Stomach Neoplasms - pathology | Maytansine - pharmacology | Immunoconjugates - immunology | Breast Neoplasms - enzymology | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Neoplasms - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Female | Camptothecin - immunology | Receptor, ErbB-2 - immunology | Camptothecin - analogs & derivatives | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Maytansine - analogs & derivatives | Neoplasms - enzymology | Stomach Neoplasms - immunology | Animals | Breast Neoplasms - genetics | Bystander Effect - drug effects | Breast Neoplasms - pathology | Mice, Nude | Neoplasms - immunology | Cell Membrane Permeability - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Antibodies, Monoclonal, Humanized - immunology | Neoplasms - pathology | Camptothecin - pharmacology | Maytansine - immunology | Trastuzumab | Viral antibodies | Epidermal growth factor | Imaging systems | Antibodies | Permeability | Drug therapy | Biopharmaceutics | Tumors | Antigens | Hematology | Laboratories | Toxicity | DNA topoisomerase | Polymerization | Clinical trials | Cytotoxicity | Breast cancer | ErbB-2 protein | Stomach cancer | Hypotheses | Antitumor agents | Xenografts | Antitumor activity | Lymphomas | Drug dosages | Payloads | Index Medicus | Original
Journal Article
PloS one, ISSN 1932-6203, 2010, Volume 5, Issue 11, p. e14117
... EGFR is dominant for growth signaling, but not in cell lines where EGFR signaling is absent. A luciferase reporter containing... 
Fibroblast Growth Factor 7 - pharmacology | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Coculture Techniques | Humans | Lung Neoplasms - metabolism | Fibroblast Growth Factor 2 - pharmacology | Lung Neoplasms - pathology | Extracellular Signal-Regulated MAP Kinases - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Fibroblasts - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Drug Resistance, Neoplasm - genetics | Signal Transduction - drug effects | Fibroblasts - drug effects | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Fibroblasts - cytology | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Tyrosine | Phenols | Fibroblast growth factors | RNA | Analysis | Luciferase | Fibroblast growth factor | Biotechnology | Transcription | Gene regulation | Lung cancer | Biology | Kinases | Cell adhesion & migration | Morphogenesis | Epidermal growth factor | Fibroblast growth factor receptor 7 | Gefitinib | Protein-tyrosine kinase | Fibroblast growth factor receptor 2 | Fibroblast growth factor 2 | Epidermal growth factor receptors | Extracellular signal-regulated kinase | Non-small cell lung carcinoma | Gene expression | Src protein | Self sufficiency | Pulmonary hypertension | Studies | Signaling | Inhibitors | Monoclonal antibodies | Ligands | Mutation | Tumors | Fibroblast growth factor receptors
Journal Article
Nature (London), ISSN 1476-4687, 2012, Volume 487, Issue 7408, pp. 505 - 509
Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy(1). However, the efficacy of kinase inhibitors in... 
CELL LUNG-CANCER | SURVIVAL | HETEROGENEITY | ACTIVATION | RECEPTOR TYROSINE KINASES | THERAPY | MET AMPLIFICATION | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | SENSITIVITY | TUMOR-CELLS | Receptor, ErbB-2 - genetics | Humans | Receptor, ErbB-2 - metabolism | Melanoma - enzymology | Phosphatidylinositol 3-Kinases - metabolism | Hepatocyte Growth Factor - pharmacology | Breast Neoplasms - metabolism | Melanoma - genetics | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cell Survival - drug effects | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Breast Neoplasms - drug therapy | Hepatocyte Growth Factor - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Breast Neoplasms - genetics | Signal Transduction - drug effects | Breast Neoplasms - pathology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Ligands | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Mitogen-Activated Protein Kinases - metabolism | Antimitotic agents | Physiological aspects | Antineoplastic agents | Growth factors | Health aspects | Phosphotransferases | Substance abuse treatment | Epidermal growth factor | Rodents | Biomarkers | Breast cancer | Insulin-like growth factors | Kinases | Drug resistance | Tumors
Journal Article
Journal Article
Nature (London), ISSN 1476-4687, 2015, Volume 526, Issue 7572, pp. 263 - 267
.... In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies cetuximab and panitumumab, which prevent epidermal growth factor receptor (EGFR) activation(1... 
PANITUMUMAB | THERAPY | MULTIDISCIPLINARY SCIENCES | SEQUENCE | ACQUIRED-RESISTANCE | SOMATIC MUTATION | IDENTIFICATION | GENE COPY NUMBER | ACTIVATING MUTATIONS | BREAST | INSIGHTS | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Genomics | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Molecular Targeted Therapy | Receptor, Fibroblast Growth Factor, Type 1 - genetics | MAP Kinase Kinase 1 - genetics | Colorectal Neoplasms - drug therapy | Female | Antineoplastic Agents - pharmacology | Insulin Receptor Substrate Proteins - genetics | Colorectal Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Cetuximab - pharmacology | DNA Copy Number Variations - genetics | Mutation - genetics | Genome, Human - genetics | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Exome - genetics | Animals | Receptor, Platelet-Derived Growth Factor alpha - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Gene mutations | Colorectal cancer | Drug metabolism | Genetic aspects | Identification and classification | Health aspects | Proteins | Epidermal growth factor | Genes | Clinical trials | Mutation | Kinases | Cancer therapies | Tumors
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 31, pp. 4769 - 4777
...–epidermal growth factor (EGFR) monoclonal antibodies is established. In patients with non... 
K-RAS MUTATIONS | RESECTED STAGE-I | PROGNOSTIC IMPACT | ONCOLOGY | RANDOMIZED PHASE-III | EML4-ALK FUSION GENE | BRONCHIOLOALVEOLAR-CARCINOMA | 1ST-LINE TAXANE/CARBOPLATIN | MOLECULAR PREDICTORS | GENE COPY NUMBER | ONCOGENE ACTIVATION | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Predictive Value of Tests | Receptor, Epidermal Growth Factor - genetics | Translocation, Genetic | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Paclitaxel - pharmacology | Microtubule-Associated Proteins - genetics | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | ras Proteins - metabolism | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Patient Selection | Antibodies, Monoclonal, Humanized | Protein-Tyrosine Kinases - genetics | Receptor, Epidermal Growth Factor - metabolism | Serine Endopeptidases - genetics | Biomarkers, Tumor - metabolism | Cell Cycle Proteins - genetics | Antineoplastic Agents - pharmacology | Cetuximab | Precision Medicine | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Proto-Oncogene Proteins - genetics | Clinical Trials as Topic | Cisplatin - pharmacology | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives
Journal Article
Pharmacology & therapeutics (Oxford), ISSN 0163-7258, 2017, Volume 171, pp. 30 - 42
Pericytes are a heterogeneous population of cells located in the blood vessel wall. They were first identified in the 19th century by Rouget, however their... 
Pericytes | Perivascular stem cells | Diabetic retinopathy | Diabetic nephropathy | Pericyte fibrosis | Cancer stem cells | DIABETIC-RETINOPATHY | Cancer stern cells | VEGF-A | BLOOD-BRAIN-BARRIER | MESENCHYMAL STEM-CELLS | EPITHELIUM-DERIVED FACTOR | HIGH GLUCOSE | PHARMACOLOGY & PHARMACY | STROMAL CELLS | TUMOR-GROWTH | GLYCATION END-PRODUCTS | ENDOTHELIAL GROWTH-FACTOR | Neoplasms - therapy | Animals | Diabetes Mellitus - physiopathology | Vascular Diseases - therapy | Diabetes Mellitus - therapy | Humans | Pericytes - cytology | Ischemia - therapy | Vascular Diseases - physiopathology | Ischemia - physiopathology | Molecular Targeted Therapy | Neoplasms - pathology | Blood circulation disorders | Therapeutics | Homeopathy | Materia medica and therapeutics | Impotence | Diabetic nephropathies | T cells | Muscle proteins | Cardiovascular agents | Blood coagulation factor VIII | Interleukins | Chronic kidney failure | Type 1 diabetes | Stem cells | Vascular endothelial growth factor | Mitogens | Protein kinases | Growth factors | UUO, unilateral ureteric obstruction | EGFR, EGF receptor | EMT, epithelial-mesenchymal transition | SFT, solitary fibrous tumour | DAN, diabetic autonomous neuropathy | ECM, extracellular matrix | NRF2, nuclear factor (erythroid-derived 2)-like 2 | IL-6, interleukin 6 | PSC, perivascular stem cell | BBB, blood-brain barrier | SOD, super oxide dismutase | HIF, hypoxia inducible factor | ED, erectile dysfunction | SDF-1, stromal derived factor 1 | RAGE, receptors of AGEs | CKD, chronic kidney disease | MMP, matrix metalloproteinases | MDSC, myeloid-derived suppressor cells | DN, diabetic nephropathy | TGF β, transforming growth factor β | PDL-1, programmed death-ligand 1 | ANG2, angiopoietin-2 | Olmfl3, Olfactomedin-like 3 | VEGF, vascular endothelial growth factor | AGE, Advanced Glycation End-Products | EC, endothelial cells | NG2, neural | R, ischemia-reperfusion | MSC, mesenchymal stromal cell | MF-EGF8, milk fat globule epidermal growth factor VIII | IL-8, interleukin 8 | glial antigen 2 | T1D, type 1 diabetic | PDGFb, platelet-derived growth factor B | MAPK, mitogen-activated protein kinase | PDGFRβ, platelet derived growth factor receptor β | DR, diabetic retinopathy | CNS, blood-retinal barrier | HB-EGF, heparin-binding EGF-like growth factor | HPC, hemangiopericytoma | PDR, proliferative diabetic retinopathy | DME, diabetic macular oedema | GFR, glomerular filtration rate | MI, myocardial infarction | SMA, smooth muscle actin | CSC, cancer stem cell | NPDR, non-proliferative diabetic retinopathy | T2D, type 2 diabetic | ROS, reactive oxygen species | Treg, regulatory T cells | BRB, blood-retina barrier | PKC, protein kinase C | DPN, diabetic peripheral neuropathy | TME, tumour microenvironment | ANG1, angiopoietin-1 | GSC, glioblastoma CSC | iPS, induced pluripotent stem cells | GSI, g-secretase inhibitor | FGF-9, fibroblastic growth factor 9 | PEDF, Pigment Epithelium-Derived Factor
Journal Article